Sensorion receives US FDA Rare Pediatric Disease Designation for gene therapy 07-Nov-2022 By Rachel Arthur Sensorion, a biotech specializing in therapies for hearing loss disorders, has been granted Rare Pediatric Disease Designation from the US Food and Drug Administration (FDA) for its lead gene therapy candidate, OTOF-GT.
Sensorion and Institut Pasteur announce new gene therapy collaboration for hearing loss 16-Feb-2021 By Rachel Arthur Sensorion and Institut Pasteur have announced a third gene therapy collaboration: which will target pediatric and adult deafness segments.
Hired and Retired: Appointments at the cutting edge 24-Feb-2020 By Ben Hargreaves This month there have been a number of changes in the leadership of organizations working on biosimilars and in the advanced therapeutic space.